摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-[4-(1-cyanocyclobutylamino)phenyl]propanoic acid | 915086-86-1

中文名称
——
中文别名
——
英文名称
3-[4-(1-cyanocyclobutylamino)phenyl]propanoic acid
英文别名
3-[4-(1-cyanocyclobutylamino)-phenyl]-propionic acid;3-[4-[(1-Cyanocyclobutyl)amino]phenyl]propanoic acid
3-[4-(1-cyanocyclobutylamino)phenyl]propanoic acid化学式
CAS
915086-86-1
化学式
C14H16N2O2
mdl
——
分子量
244.293
InChiKey
QEDOFQNPCUXRIW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    18
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    73.1
  • 氢给体数:
    2
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER
    申请人:The Regents of the University of California
    公开号:EP3106162A1
    公开(公告)日:2016-12-21
    The present invention relates to a particular diarylhydantoin compound acting by reducing the androgen-receptor(AR) activity. The compound is thus for use in treatment of diseases such as hormone refractory cancer, prostate cancer, benign prostate hyperplasia, breast cancer and ovarian cancer.
    本发明涉及一种特定的二苯基异噁唑酮化合物,通过减少雄激素受体(AR)活性发挥作用。因此,该化合物可用于治疗激素难治性癌症、前列腺癌、良性前列腺增生、乳腺癌和卵巢癌等疾病。
  • TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS
    申请人:Sawyers Charles L.
    公开号:US20120295944A1
    公开(公告)日:2012-11-22
    The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    本发明涉及二苯基异噁唑烷酮化合物,包括二苯基硫代异噁唑烷酮,以及合成它们和在治疗荷尔蒙难治性前列腺癌中使用它们的方法。
  • DIARYLHYDANTOIN COMPOUNDS
    申请人:The Regents of the University of California
    公开号:US20150112082A1
    公开(公告)日:2015-04-23
    The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    本发明涉及二芳基酰脲化合物,包括二芳基硫酰脲,以及合成它们和在治疗激素难治性前列腺癌中使用它们的方法。
  • Diarylhydantoin compounds
    申请人:Sawyers L. Charles
    公开号:US20070004753A1
    公开(公告)日:2007-01-04
    The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
    本发明涉及二芳基异噁唑酮化合物,包括二芳基硫代异噁唑酮,以及合成它们和将它们用于治疗激素难治性前列腺癌的方法。
  • Structure−Activity Relationship for Thiohydantoin Androgen Receptor Antagonists for Castration-Resistant Prostate Cancer (CRPC)
    作者:Michael E. Jung、Samedy Ouk、Dongwon Yoo、Charles L. Sawyers、Charlie Chen、Chris Tran、John Wongvipat
    DOI:10.1021/jm901488g
    日期:2010.4.8
    A structure activity relationship study was carried out on a series of thiohydantoins and their analogues 14 which led to the discovery of 92 (MDV3100) as the clinical candidate for the treatment of hormone refractory prostate cancer.
查看更多